JAK2 mutation status, hemostatic risk factors and thrombophilic factors in essential thrombocythemia (ET) patients
The recently discovered JAK2 V617F point mutation, found in 50–60% of ET patients, has been reported to be associated with a higher risk of thrombotic events. In this study, we explored if JAK2 V617F mutation, or coexisting thrombophilic and hemostatic risk factors, contributed to thes...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Via Medica
2011-07-01
|
Series: | Folia Histochemica et Cytobiologica |
Subjects: | |
Online Access: | http://czasopisma.viamedica.pl/fhc/article/view/4123 |
id |
doaj-bfd32038b2524a3d8fab1128a95686dd |
---|---|
record_format |
Article |
spelling |
doaj-bfd32038b2524a3d8fab1128a95686dd2020-11-24T22:46:10ZengVia MedicaFolia Histochemica et Cytobiologica0239-85081897-56312011-07-0149226727110.5603/4123JAK2 mutation status, hemostatic risk factors and thrombophilic factors in essential thrombocythemia (ET) patientsAnna DmoszyńskaMartyna Kandefer-SzerszeńAnna M. KowalskaTomasz GromekAdam Walter-CroneckKatarzyna WejkszaSylwia ChocholskaKsenia BykowskaAleksandra NowaczyńskaBożena SokołowskaThe recently discovered JAK2 V617F point mutation, found in 50–60% of ET patients, has been reported to be associated with a higher risk of thrombotic events. In this study, we explored if JAK2 V617F mutation, or coexisting thrombophilic and hemostatic risk factors, contributed to these complications. We examined 32 patients with ET, and looked for pathogenetic JAK2 V617F mutation and prothrombotic genes mutations: factor V Leiden, prothrombin and MTHFR. We also evaluated plasma levels of fibrinogen, factors VIII and XII, AT, protein C, protein S and serum level of homocysteine. Urokinase concentration was assessed in patients’ plasma as well as platelet lysates. There was no difference in the number of thrombotic complications between ET patients with and without JAK2 mutation. However, we found a number of thrombophilic and hemostatic risk factors that could contribute to thrombotic complications in ET patients. (Folia Histochemica et Cytobiologica 2011; Vol. 49, No. 2, pp. 267–271)http://czasopisma.viamedica.pl/fhc/article/view/4123JAK2 mutationETthrombophilic factors |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Anna Dmoszyńska Martyna Kandefer-Szerszeń Anna M. Kowalska Tomasz Gromek Adam Walter-Croneck Katarzyna Wejksza Sylwia Chocholska Ksenia Bykowska Aleksandra Nowaczyńska Bożena Sokołowska |
spellingShingle |
Anna Dmoszyńska Martyna Kandefer-Szerszeń Anna M. Kowalska Tomasz Gromek Adam Walter-Croneck Katarzyna Wejksza Sylwia Chocholska Ksenia Bykowska Aleksandra Nowaczyńska Bożena Sokołowska JAK2 mutation status, hemostatic risk factors and thrombophilic factors in essential thrombocythemia (ET) patients Folia Histochemica et Cytobiologica JAK2 mutation ET thrombophilic factors |
author_facet |
Anna Dmoszyńska Martyna Kandefer-Szerszeń Anna M. Kowalska Tomasz Gromek Adam Walter-Croneck Katarzyna Wejksza Sylwia Chocholska Ksenia Bykowska Aleksandra Nowaczyńska Bożena Sokołowska |
author_sort |
Anna Dmoszyńska |
title |
JAK2 mutation status, hemostatic risk factors and thrombophilic factors in essential thrombocythemia (ET) patients |
title_short |
JAK2 mutation status, hemostatic risk factors and thrombophilic factors in essential thrombocythemia (ET) patients |
title_full |
JAK2 mutation status, hemostatic risk factors and thrombophilic factors in essential thrombocythemia (ET) patients |
title_fullStr |
JAK2 mutation status, hemostatic risk factors and thrombophilic factors in essential thrombocythemia (ET) patients |
title_full_unstemmed |
JAK2 mutation status, hemostatic risk factors and thrombophilic factors in essential thrombocythemia (ET) patients |
title_sort |
jak2 mutation status, hemostatic risk factors and thrombophilic factors in essential thrombocythemia (et) patients |
publisher |
Via Medica |
series |
Folia Histochemica et Cytobiologica |
issn |
0239-8508 1897-5631 |
publishDate |
2011-07-01 |
description |
The recently discovered JAK2 V617F point mutation, found in 50–60% of ET patients, has been reported to be associated with a higher risk of thrombotic events. In this study, we explored if JAK2 V617F mutation, or coexisting thrombophilic and hemostatic risk factors, contributed to these complications. We examined 32 patients with ET, and looked for pathogenetic JAK2 V617F mutation and prothrombotic genes mutations: factor V Leiden, prothrombin and MTHFR. We also evaluated plasma levels of fibrinogen, factors VIII and XII, AT, protein C, protein S and serum level of homocysteine. Urokinase concentration was assessed in patients’ plasma as well as platelet lysates. There was no difference in the number of thrombotic complications between ET patients with and without JAK2 mutation. However, we found a number of thrombophilic and hemostatic risk factors that could contribute to thrombotic complications in ET patients. (Folia Histochemica et Cytobiologica 2011; Vol. 49, No. 2, pp. 267–271) |
topic |
JAK2 mutation ET thrombophilic factors |
url |
http://czasopisma.viamedica.pl/fhc/article/view/4123 |
work_keys_str_mv |
AT annadmoszynska jak2mutationstatushemostaticriskfactorsandthrombophilicfactorsinessentialthrombocythemiaetpatients AT martynakandeferszerszen jak2mutationstatushemostaticriskfactorsandthrombophilicfactorsinessentialthrombocythemiaetpatients AT annamkowalska jak2mutationstatushemostaticriskfactorsandthrombophilicfactorsinessentialthrombocythemiaetpatients AT tomaszgromek jak2mutationstatushemostaticriskfactorsandthrombophilicfactorsinessentialthrombocythemiaetpatients AT adamwaltercroneck jak2mutationstatushemostaticriskfactorsandthrombophilicfactorsinessentialthrombocythemiaetpatients AT katarzynawejksza jak2mutationstatushemostaticriskfactorsandthrombophilicfactorsinessentialthrombocythemiaetpatients AT sylwiachocholska jak2mutationstatushemostaticriskfactorsandthrombophilicfactorsinessentialthrombocythemiaetpatients AT kseniabykowska jak2mutationstatushemostaticriskfactorsandthrombophilicfactorsinessentialthrombocythemiaetpatients AT aleksandranowaczynska jak2mutationstatushemostaticriskfactorsandthrombophilicfactorsinessentialthrombocythemiaetpatients AT bozenasokołowska jak2mutationstatushemostaticriskfactorsandthrombophilicfactorsinessentialthrombocythemiaetpatients |
_version_ |
1725685931240849408 |